Whalesbook
The results were primarily driven by a widening gap between cost and revenue growth, a detail that warrants closer inspection amid bullish analyst sentiment. A recent report from Motilal Oswal reaffirmed its confidence in UTI AMC, citing strong projected growth in assets under management (AUM). However, the underlying operational metrics from the third quarter of fiscal year 2026 paint a more complex picture of the asset manager's health.
The Profitability Challenge
UTI AMC's operating revenue for the quarter ending December 2025 rose a modest 5% year-over-year to INR 3.9 billion. In stark contrast, total operating expenses climbed 16% to INR 2.1 billion over the same period. This mismatch led to a direct hit on profitability, with the EBITDA margin falling by 520 basis points to 45.6%. Compounding the issue, the yield on management fees, a key indicator of revenue efficiency, declined to 40.1 basis points from 42.6 basis points in the prior year's quarter. While the reported EBITDA of INR 1.8 billion beat some estimates, the negative year-over-year trend in core profitability metrics has not gone unnoticed by the market, with the stock showing volatility following the earnings announcement. [10, 13]
Valuation and Sector Context
Currently, UTI AMC trades at a trailing twelve-month price-to-earnings (P/E) ratio of approximately 19.6 to 22.1. [2, 11] This valuation appears significantly lower than its larger peers, such as HDFC AMC, which trades at a P/E of around 37-39, and Nippon India AMC, with a P/E of about 38. [6, 16, 19, 21] While this might suggest a value opportunity, the discount also reflects the market's concern over persistent market share challenges and the recent margin squeeze. [5] The broader financial sector, represented by the Nifty Financial Services Index, has seen sluggish performance year-to-date, posting a decline of around 1.36% in the last month, creating a challenging backdrop for asset managers. [20, 26]
Future Outlook
Motilal Oswal's forecast anticipates a compound annual growth rate (CAGR) of 15% in AUM, 11% in revenue, and 15% in core profit after tax between fiscal years 2025 and 2028. This outlook is supported by a consensus analyst view that suggests investors can buy the stock, with 80% of analysts covering the company holding this opinion. [12] However, for this growth to translate into shareholder value, the company must address the divergence between its expense growth and revenue generation. Investors will be closely monitoring whether UTI AMC can stabilize its margins and improve operational leverage in the upcoming quarters to justify the optimistic price targets set by brokerages.